Zobrazeno 1 - 10
of 289
pro vyhledávání: '"M. Monconduit"'
Autor:
Margaret Macro, Thierry Facon, Christian Berthou, Norbert Najman, Gerald Marit, Denis Caillot, Bernard Rio, Thomas Matthes, Lotfi Benboubker, Michel Attal, Philippe Casassus, Jean-Jacques Sotto, Chantal Doyen, François Guilhot, Bernard Grosbois, Laurent Voillat, Philippe Moreau, Jérôme Jaubert, Jean-Luc Harousseau, Frédéric Maloisel, Véronique Dorvaux, Cyrille Hulin, Bernard Pignon, Jean-Gabriel Fuzibet, M. Monconduit, Sylvie François, Mauricette Michallet, Régis Bataille
Publikováno v:
Blood. 99:731-735
High-dose therapy has become a common treatment for myeloma. The objective of this study (Intergroupe Francophone du Myélome [IFM] 9502 trial) was to compare in a prospective and randomized trial the 2 most widely used conditioning regimens before a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a201f65f25b1630ff06c7cf1f81e3876
https://doi.org/10.1182/blood.v99.3.731
https://doi.org/10.1182/blood.v99.3.731
Autor:
Marc Zandecki, Jean-Marie Scheiff, Jean-Louis Michaux, Claire Mathiot, Bernard Grosbois, Jean E. Goasguen, Marie Bizet, Beatrice Ly-Sunnaram, M. Monconduit, Thierry Facon
Publikováno v:
Leukemia Research. 23:1133-1140
The relationship between plasmablastic cells and outcome in multiple myeloma (MM) has been established for nearly 15 years. But the assessment of these cells is not easy to perform and it allows the identification of only a small proportion of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49de16185dbbfc0ba821d0d53b531f54
https://doi.org/10.1016/s0145-2126(99)00132-0
https://doi.org/10.1016/s0145-2126(99)00132-0
Autor:
B. Lenormand, M.-C. Béné, J.-F. Lesesve, C. Bastard, H. Tilly, M.-P. Lefranc, G.-C. Faure, R. Garand, A. Falkenrodt, G. Kandel, E. Solary, M. Maynadié, M.-P. Callat, F. Thouret, M. Monconduit, J.-P. Vannier, null The Groupe D'Etude Immunologique de
Publikováno v:
Leukemia & Lymphoma. 28:329-342
The less differentiated stage (CD10-) of B-lineage acute lymphoblastic leukaemia (ALL) described as preB1-ALL in the GEIL nomenclature, accounts for less than 10% of ALL. It is classically considered to be associated with translocation (4;11)(q21;q23
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::014ccdec4cd07cd17dc3fca4900e44b4
https://doi.org/10.3109/10428199809092688
https://doi.org/10.3109/10428199809092688
Autor:
Sylvie Beufé, Francloise Charbonnier, Viviane Moreau, M. Monconduit, Jeanne-Yvonne Borg, Thierry Frebourg, Marc Vasse
Publikováno v:
British Journal of Haematology. 89:659-662
The activated protein C (APC) resistance phenotype results from a mutation at one of the cleavage sites of factor V by APC (Q506). We describe a large family with an APC resistance phenotype and without any other detectable coagulation defect, includ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53463fec3b275867d9ffaab40a39657e
https://doi.org/10.1111/j.1365-2141.1995.tb08384.x
https://doi.org/10.1111/j.1365-2141.1995.tb08384.x
Autor:
Jeannette Soria, S. S. Mirshahi, Marc Vasse, Claudine Soria, M. Monconduit, M. Mirshahi, Jeanne-Yvonne Borg
Publikováno v:
Blood Coagulation & Fibrinolysis. 4:143-147
As fibrinogen is an independent risk factor for arterial thrombosis we were interested in analysing the mechanism controlling fibrinogen biosynthesis. In this work, we showed that incubation of monocytes with lymphocytes increased hepatocyte stimulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfb085cbbe04d512e6ae246e99a64e9f
https://doi.org/10.1097/00001721-199302000-00025
https://doi.org/10.1097/00001721-199302000-00025
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1180:53-57
Hb Rouen (alpha 140(HC2) Tyr--His) is a moderately high oxygen-affinity variant that was found in coincidence with polycythemia vera in a French patient. This hemoglobin provides an example of an alteration of the C-terminus of the alpha-chain, a reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f13c712335a92a376198812b92b482
https://doi.org/10.1016/0925-4439(92)90026-j
https://doi.org/10.1016/0925-4439(92)90026-j
Autor:
M. Monconduit
Publikováno v:
La Revue de Médecine Interne. 13:315-318
In 1992, the Melphalan-Prednisone (M. P.) protocol remains a standard treatment of multiple myeloma even if a lot of new ways have been investigated during the last years. Polychemotherapies may appear better than M.P. for high tumor mass myeloma. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfb6a0288d8b984f9d22d817b2b9dd3b
https://doi.org/10.1016/s0248-8663(05)80310-8
https://doi.org/10.1016/s0248-8663(05)80310-8
Autor:
G. Teixeira, B. Lenormand, E. Sumereau-Dassin, Dominique Bastit, M. Monconduit, J. P. Vannier, P. Jean, Hervé Tilly, Hubert Piguet, D. Fardoun
Publikováno v:
American Journal of Hematology. 39:172-175
Some patients suffering from malignancies may benefit of myeloablative chemotherapy followed by hematological reconstitution with autologous peripheral blood reinfusion. A quick evaluation of the number of hematopoietic progenitors present in leukaph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186e157b7135e256914cc745ff18b19b
https://doi.org/10.1002/ajh.2830390304
https://doi.org/10.1002/ajh.2830390304
Autor:
J. Thomas, M. van Glabbeke, M. Monconduit, Riet Somers, J. A. M. van Unnik, Bernard Caillou, Nicole Duez, D Bron, J. M. V. Burgers, Anton Hagenbeek, Jean-Marc Cosset, C De Wolf-Peeters, J. C. Kluin-Nelemans, J. Wagener, R. Regnier, Patrice Carde, A. Cattan, Evert M. Noordijk, A. Tanguy, B. de Pauw, M. Hayat, Jacques Bosq, J.H. Meerwaldt, J. Lustinan-Marechal, M. Tubiana, P. Van Heerde, E. van der Schueren
Publikováno v:
Annals of Oncology. 2:431-435
Summary A first-generation CHOP-like cyclic combination chemotherapy (CT) regimen using cyclophosphamide 600 mg/m2 IV d1, hydroxorubicin (doxorubicin) 50 mg/m2 IV d1, VM26 60 mg/m2 IV d1, and prednisone 40 mg/m2 PO d1–5 (CHVmP) was compared to a se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bc60373ba494f9f575a2febf99aea88
https://doi.org/10.1093/oxfordjournals.annonc.a057979
https://doi.org/10.1093/oxfordjournals.annonc.a057979
Publikováno v:
Cancer Genetics and Cytogenetics. 52:135-138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9935f07f034d9442c3540afc6e43eb41
https://doi.org/10.1016/0165-4608(91)90064-2
https://doi.org/10.1016/0165-4608(91)90064-2